Achmea Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-5,847
| Closed | -$1.38M | – | 358 |
|
|
2024
Q4 | $1.38M | Buy |
5,847
+105
| +2% | +$24.7K | 0.02% | 320 |
|
|
2024
Q3 | $1.58M | Buy |
5,742
+1,728
| +43% | +$475K | 0.03% | 326 |
|
|
2024
Q2 | $975K | Hold |
4,014
| – | – | 0.02% | 354 |
|
|
2024
Q1 | $599K | Hold |
4,014
| – | – | 0.01% | 397 |
|
|
2023
Q4 | $769K | Sell |
4,014
-4,911
| -55% | -$941K | 0.02% | 416 |
|
|
2023
Q3 | $1.58M | Sell |
8,925
-184
| -2% | -$32.6K | 0.03% | 341 |
|
|
2023
Q2 | $1.73M | Buy |
9,109
+1,698
| +23% | +$322K | 0.04% | 350 |
|
|
2023
Q1 | $1.48M | Buy |
7,411
+2,919
| +65% | +$585K | 0.04% | 339 |
|
|
2022
Q4 | $1M | Buy |
4,492
+4,308
| +2,341% | +$959K | 0.03% | 400 |
|
|
2022
Q3 | $37K | Hold |
184
| – | – | ﹤0.01% | 573 |
|
|
2022
Q2 | $27K | Hold |
184
| – | – | ﹤0.01% | 579 |
|
|
2022
Q1 | $30K | Hold |
184
| – | – | ﹤0.01% | 593 |
|
|
2021
Q4 | $31K | Hold |
184
| – | – | ﹤0.01% | 322 |
|
|
2021
Q3 | $35K | Buy |
+184
| New | +$35K | ﹤0.01% | 548 |
|
|
2020
Q3 | – | Sell |
-12,459
| Closed | -$1.85M | – | 483 |
|
|
2020
Q2 | $1.85M | Sell |
12,459
-6,360
| -34% | -$942K | 0.06% | 190 |
|
|
2020
Q1 | $2.05M | Buy |
18,819
+11,425
| +155% | +$1.24M | 0.09% | 148 |
|
|
2019
Q4 | $852K | Hold |
7,394
| – | – | 0.03% | 388 |
|
|
2019
Q3 | $595K | Hold |
7,394
| – | – | 0.02% | 413 |
|
|
2019
Q2 | $537K | Hold |
7,394
| – | – | 0.02% | 435 |
|
|
2019
Q1 | $691K | Hold |
7,394
| – | – | 0.03% | 371 |
|
|
2018
Q4 | $539K | Hold |
7,394
| – | – | 0.02% | 380 |
|
|
2018
Q3 | $647K | Hold |
7,394
| – | – | 0.02% | 410 |
|
|
2018
Q2 | $728K | Hold |
7,394
| – | – | 0.03% | 399 |
|
|
2018
Q1 | $880K | Hold |
7,394
| – | – | 0.03% | 395 |
|
|
2017
Q4 | $939K | Buy |
+7,394
| New | +$939K | 0.03% | 386 |
|